Down Syndrome Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2032

The Down Syndrome market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as AC Immune, Annovis Bio, Alzheon, OPKO Health, Inc., Aelis Farma, Eisai Inc., Elixirgen Therapeutics, Aphios Therapeutics, Avanti Biosciences, AelisFarma, Kinopharma, NeuroNascent, Inc., Pharmasum Therapeutics, Hoffmann-La Roche, AstraZeneca

[Nevada, United States] - DelveInsight's "Down Syndrome Market Insights, Epidemiology, and Market Forecast 2032." report offers a detailed examination of Down Syndrome, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Down Syndrome Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/report-store/down-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Down Syndrome Market Report:
The Down Syndrome market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2019-2032).
In October, 2024: AstraZeneca announced that the purpose of their study is to measure the safety, PK, occurrence of ADA to nirsevimab, and anti-RSV neutralizing Ab in Japanese children with certain health conditions or preterm infants aged ≤12 months.
In September, 2024: Inspire Medical Systems, Inc. announced a prospective, single-arm study conducted under a common implant and follow-up protocol. The objective will be to follow fifty-seven (57) adolescents and young adults (10-21 years of age), with Down syndrome, moderate to severe sleep apnea, and post-adenotonsillectomy, for 12 months after undergoing implant of the Inspire Upper Airway Stimulation (UAS) System.
In June, 2024: Aelis Farma announced that AEF0217-102 clinical trial assesses the safety, tolerability, plasma exposure and preliminary indications of pharmacodynamic activity of AEF0217 in female and male adult participants with Down syndrome between 18 and 35 years old.
In May, 2024: AC Immune SA announced that the purpose of their study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndrome.
According to Presson et al. (2013), estimation the January 2008 population prevalence of Down syndrome asapproximately 250,700, which estimated to a prevalence of 8.27 people with Down syndrome per10,000population.
According to Graaf et al. (2016), the estimated the population prevalence for Down syndrome is1 in 1,499 inthe US, representing about 206,366 people with Down syndrome.
According to Antonarakis (2020), the lifetime prevalence of Down syndrome is increasing substantially as theglobal population grows. For example, in the US, the population prevalence of Down syndrome increasedfrom ~50,000 in 1950 (3.3 per 10,000 individuals) to ~212,000 in 2013 (6.7 per 10,000 individuals).
Key Down Syndrome Companies are as follows: AC Immune, Annovis Bio, Alzheon, OPKO Health, Inc., Aelis Farma, Eisai Inc., Elixirgen Therapeutics, Aphios Therapeutics, Avanti Biosciences, AelisFarma, Kinopharma, NeuroNascent, Inc., Pharmasum Therapeutics, Hoffmann-La Roche, AstraZeneca
Key Down Syndrome Therapies are as follow: AEF0217, Memantine, Donepezil HCl, E2020-Donepezil hydrochloride, RG1662, ELND005, ACI-24.060, Benralizumab, CD101, Caspofungin, Fluconazole, Lofexidine
Launching multiple stage Down Syndrome pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Down Syndrome market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/sample-request/down-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Down Syndrome Overview:
Down syndrome also known as trisomy 21 is a genetic chromosome 21 disorder causing developmental andintellectual delays. It's caused when abnormal cell division results in extra genetic material fromchromosome 21. This extra copy changes how the baby's body and brain develop, which can cause bothmental and physical challenges for the baby.

Down Syndrome Epidemiology Segmentation:
The Down Syndrome market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
Down Syndrome Diagnosed Prevalent Cases
Down Syndrome Type-specific Cases
Down Syndrome Gender-specific Cases
Down Syndrome Age-specific Cases

For more information about Down Syndrome companies working in the treatment market, visit https://www.delveinsight.com/sample-request/down-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Down Syndrome Market Insights
A variety of therapies can be used in early intervention programs and throughout a person's life to promote thegreatest possible development, independence, and productivity. While some physical deficits in Down syndromemay be corrected with surgery,medications are often used to manage various comorbid health conditions inindividuals with Down syndrome.

Anticonvulsants such as carbamazepine and phenytoin provide seizure control in some patients, however, it hasthe potential to further exacerbate other comorbid conditions and effects of Down syndrome.
Besides, non-pharmacological treatments like physical, speech, occupational, and behavioral therapies are usedearly in life to promote the greatest possible development, independence, and productivity.
Respiratory disorders are common in people with Down syndrome. Impaired immune system function combinedwith respiratory tract defects make respiratory diseases a serious concern. Antibiotic therapyor inhaledbronchodilators may be needed to treat some respiratory problems related with Down syndrome.

Down Syndrome Drugs Uptake
AEF0217, investigated by Aelis Farma is signaling specific inhibitors of the CB1 receptor (CB1-SSi). The CB1 is the main receptor of the brain's system that is responsible for regulating several physiological and cognitive processes.
ACI-24.060 is being developed by AC Immune SA. ACI-24 is an anti-Abeta vaccine candidate designed to generate antibodies specifically targeting misfolded Abeta to prevent accumulation and enhance clearance of amyloid plaques.
There are preclinical and early phase assets under development by Kino Pharma, NeuroNascent (NNI-351), and Avanti biosciences (ABI-02).

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/down-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Down Syndrome Therapies and Key Companies:
AEF0217: Aelis Farma
Memantine: University of Colorado, Denver
Donepezil HCl: Eisai Inc.
E2020-Donepezil hydrochloride: Eisai Co., Ltd.
RG1662: Hoffmann-La Roche
ELND005: OPKO Health, Inc.
ACI-24.060: AC Immune SA
Benralizumab: AstraZeneca
CD101, Caspofungin, Fluconazole: Cidara Therapeutics Inc.
Lofexidine: USWM, LLC

Down Syndrome Epidemiology:
Down Syndrome is one of the most common chromosomal abnormalities worldwide. The incidence rate of the condition is closely linked to maternal age, with older mothers at a higher risk of having a baby with DS
Approximately 1 in every 700-1,000 live births is affected by Down Syndrome.
The likelihood of having a child with Down Syndrome increases with maternal age. For women under 30, the incidence is about 1 in 1,000, but for women over 40, it can rise to as high as 1 in 100.
With advances in medical care, individuals with Down Syndrome now have an average life expectancy of about 60 years, compared to just 25 years in the 1980s.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/down-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Down Syndrome Market Drivers:
Advancements in Prenatal and Diagnostic Screening
Increased Awareness and Early Diagnosis
Technological Advancements in Medical Care
Government Initiatives and Support Programs

Down Syndrome Market Barriers:
Lack of Targeted Therapeutic Options
Social Stigma and Limited Access to Care
High Cost of Advanced Prenatal Screening
Limited Research and Development Funding

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/down-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Down Syndrome Market Report:
Study Period: 2019-2032
Coverage: 7MM (The United States, EU5, and Japan)
Key Down Syndrome Companies: AC Immune, Annovis Bio, Alzheon, OPKO Health, Inc., Aelis Farma, Eisai Inc., Elixirgen Therapeutics, Aphios Therapeutics, Avanti Biosciences, AelisFarma, Kinopharma, NeuroNascent, Inc., Pharmasum Therapeutics, Hoffmann-La Roche, AstraZeneca
Key Down Syndrome Therapies: AEF0217, Memantine, Donepezil HCl, E2020-Donepezil hydrochloride, RG1662, ELND005, ACI-24.060, Benralizumab, CD101, Caspofungin, Fluconazole, Lofexidine
Down Syndrome Therapeutic Assessment: Current marketed and emerging therapies
Down Syndrome Market Dynamics: Down Syndrome Market drivers and Down Syndrome barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Down Syndrome Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Down Syndrome market outlook, drug uptake, treatment scenario, and epidemiology trends, https://www.delveinsight.com/sample-request/down-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1. Key Insights
2. Executive Summary of Down Syndrome
3. Competitive Intelligence Analysis for Down Syndrome
4. Down Syndrome: Market Overview at a Glance
5. Down Syndrome: Disease Background and Overview
6. Patient Journey
7. Down Syndrome Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Down Syndrome Unmet Needs
10. Key Endpoints of Down Syndrome Treatment
11. Down Syndrome Marketed Products
12. Down Syndrome Emerging Therapies
13. Down Syndrome: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Down Syndrome
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.